---
title: "China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China"
description: "China Resources Pharma announced that its subsidiary China Resources BOYA Biotechnology Group has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administrat"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276832369.md"
published_at: "2026-02-25T04:29:39.000Z"
---

# China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China

> China Resources Pharma announced that its subsidiary China Resources BOYA Biotechnology Group has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for human coagulation factor IX. This product is used for bleeding treatment in patients with coagulation factor IX deficiency (Hemophilia B)

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources BOYA Biotechnology Group received the Clinical Trial Approval Notice for Human Coagulation Factor IX issued by the National Medical Products Administration. This product is used for bleeding treatment in patients with Coagulation Factor IX deficiency (Hemophilia B)

### Related Stocks

- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [159892.CN - ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)](https://longbridge.com/en/quote/159892.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [300294.CN - BOYA BIOLOGY](https://longbridge.com/en/quote/300294.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [159615.CN - China Southern Hang Seng Biotech ETF(QDII)](https://longbridge.com/en/quote/159615.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [589720.CN - Guotai SSE STAR Brand Name Drug ETF](https://longbridge.com/en/quote/589720.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德 UBT251 在华二期临床数据亮眼，减重效果近 20% | 诺和诺德授权药 UBT251 中国二期临床数据亮眼：用药 24 周体重最高减 19.7%（安慰剂仅 2%），公司称 “非常受鼓舞”。但受 Cagrisema 负面消息拖累，股价仍跌超 4%。诺和诺德已支付 2 亿美元首付款，总交易或达 20 | [Link](https://longbridge.com/en/news/276728466.md) |
| 上海医药获得新加坡市场批准用于抗凝药物 | 上海医药获得新加坡抗凝药物的市场批准 | [Link](https://longbridge.com/en/news/276822785.md) |
| 中国医药系统的特应性皮炎药物获得中国批准 | 中国医疗系统获得特应性皮炎药物的中国批准 | [Link](https://longbridge.com/en/news/276718382.md) |
| 中国抗体-B 获得中国 IND 批准，将 SM17 用于治疗炎症性肠病 | 中国抗体-B（SinoMab Bioscience Ltd.）已获得中国国家药品监督管理局批准，进行针对 SM17 在炎症性肠病中的研究新药申请，扩展其在特应性皮炎以外的应用。该公司已完成 I 期研究，并计划推进至 II 期临床试验。SM1 | [Link](https://longbridge.com/en/news/276765156.md) |
| Palumbo Wealth Management LLC 购入了 ProShares Ultra Nasdaq Biotech $BIB 的新股权 | Palumbo Wealth Management LLC 在第三季度收购了 ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) 的新股份，购买了 12,851 股，价值约为 766,000  | [Link](https://longbridge.com/en/news/276735169.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.